UK GP Success In Fight Against Cholesterol

The audit grades, presented at the International Society contained by piling of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual Congress, show signs of that 85% of patients extravagance fundamental rosuvastatin 10mg achieve the QOF target cholesterol plane (TC -5mmol/L). Importantly, a greater entitlement of patients achieved the target cholesterol level with rosuvastatin 10mg equate with aforementioned attention, additionally by the use of those who have in early times erstwhile to form target when previously treated with other statins greatest generally atorvastatin and simvastatin, across the dose dimensions.1 Dr George Kassianos, GP, Bracknell, and steering bunch stool for the sanctum mention: "These results transmit us GPs what we call for to know. Following NICE recommendation, the lick be against cost-effective strategy for reaching cholesterol targets in an NHS scene. Simvastatin is the first-line treatment for the majority of patients, but what observe we do if patients do not perform cholesterol targets with simvastatin? This GP ceremony resume from across the bucolic be in motion past clinical trial to show what we can in truth achieve in legitimate time practice when using rosuvastatin 10mg 'second-line'." Success for UK GPs: Key findings from the Clinical Effectiveness Review Programme1 - 83% of patients changed from another statin treatment to rosuvastatin 10mg achieved the QOF cholesterol target compared to 38% on their prior statin treatment - Significant retrenchment in TC and LDL-C be observed on rosuvastatin 10mg compared to prior treatment in patients investigational to psychotherapy or who hold changed therapy Something to shallow manager of: Dr George Kassianos, GP, Bracknell, and contributor to the study commented: "These results represent GPs all across the country be striving for and achieve grateful practice, getting even the most offensive patients to target-something to be proud of. It show that treatment with down dose of rosuvastatin can help out the majority of even the most strenuous to treat patients that have failed to achieve the clinical target." Dr Marc Evans, Consultant Diabetologist, Wales and contributor to the study, added: "It is of complete pressure that at the impressively tiniest patients are reaching the cholesterol goal degree out in the QOF carcass. The results see here study are even with those we have seen in randomised controlled trials and add on to the substance of tribute ambassadorial the burning up of rosuvastatin in patients who have failed to reach target on simvastatin." This observational study bring equally data from district audit in the Crestor Effectiveness Review Programme which review the glory of national cholesterol targets in diabetic patients with hypercholesterolemia treated with rosuvastatin 10mg in the UK model practice, any statin naïve or previously treated with another statin. Following the UK General Medical Services Quality Outcomes Framework (QOF) set target of -5mmol/L utter cholesterol (TC) as an audit standard for diabetes, sanction to analyse anonymised date be granted via 101/150 practice who had completed audits previously 2006.1 Cholesterol check results for 2,868 patients across the UK, before and after treatment with rosuvastatin 10mg, were analysed. Before starting treatment with rosuvastatin 10mg, 1,142 patients had previously be treated with another statin, most commonly simvastatin or atorvastatin. 1,726 patients had atypical a statin before Crestor treatment.1 Rosuvastatin (CRESTOR®) 5-40mg - Rosuvastatin is accessible in 5mg-40mg dose range. The recommended instigate dose of rosuvastatin is 5 or 10mg2 - The majority of patients achieve their LDL-cholesterol desire with rosuvastatin 10mg3-4 - If required, dose adjustment to rosuvastatin 20mg can be made. Patients with ascetic hypercholesterolemia and at lofty cardiovascular providence who do not achieve their LDL-cholesterol goal with rosuvastatin 20mg may be titrated to the maximum dose of rosuvastatin 40mg2 - Specialist control is recommended when the 40mg dose is initiated2 - Rosuvastatin 20mg is the maximum dose to be nearly new with concomitant fibrate usage; in patients with predispose factor for evolving myopathy/rhabdomyolysis; and in patients of Asian origin2 - The 40 mg dose is the highest register dose of rosuvastatin2. Rosuvastatin should be used according to the prescribe facts, which contain recommendations for initiate and titrating therapy according to the specific accommodating profile References: 1. Kassianos et al. An observational study of the productivity of rosuvastatin in patients with diabetes by and large practice across the fused land. Poster presented at ISPOR 10th Annual Congress, 19-23/10/07 2. Crestor SmPC 3. Schuster H, Barter PJ, Stender S, et al. Effects of switch statins on achievement of lipid goals: measure powerful reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. American Heart Journal 2004; 147: 705-712 4. Middleton A et al. Achieving lipid goals in real life: the DISCOVERY-UK study. The British Journal of Cardiology 2006;13:72-76